Abstracts tagged "Systemic Lupus Erythematosus"

Abstract Number: 0520 • ACR Convergence 2021
Leukocyte Immunoglobulin-like Receptor A3 Facilitates Neutrophil Extracellular Trap Formation in TLR7-induced Lupus Mice
Hongjiang Liu¹, Yundi Tang¹, Chen Chen² and Jianping Guo², ¹Peking University People's Hospital, Beijing, China (People's Republic), ²Peking University People’s Hospital, Beijing, China (People's Republic)
Background/Purpose: Leukocyte immunoglobulin-like receptor A3 (LILRA3) is a secreted protein belongs to LILR family. Our research group previously reported that the functional LILRA3 is a…
Abstract Number: 2 • 2019 ACR/ARP Annual Meeting
Baseline Cytotoxic Gene Expression Associates with Ustekinumab Response in Systemic Lupus Erythematosus
Loqmane Seridi¹, Matteo Cesaroni ¹, Matthew Loza ¹, Jessica Schreiter ¹, Kristen Sweet ¹, Yevgeniya Orlovsky ¹, Isabelle Baribaud ¹, Ashley Orillion ¹, Peter Lipsky ², Ronald van Vollenhoven ³, Bevra Hahn ⁴, George Tsokos ⁵, Marc Chevrier ¹, Shawn Rose ¹, Frédéric Baribaud ¹ and Jarrat Jordan ¹, ¹Janssen Research & Development, LLC, Spring House, PA, ²AMPEL BioSolutions, LLC, Charlottesville, VA, ³Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁴University of California, Los Angeles, CA, ⁵Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic Lupus Erythematous (SLE) is a clinically and biologically diverse disease, for which only one new therapy has been approved in the past 60…
Abstract Number: 2417 • 2012 ACR/ARHP Annual Meeting
Transitioning to Adulthood: Employment Experiences of Young Adults with Lupus and Juvenile Arthritis
Arif Jetha¹, E. M. Badley², Dorcas Beaton³, Paul R. Fortin⁴, Natalie J. Shiff⁵, Alan M. Rosenberg⁶, Lori B. Tucker⁷, Dianne P. Mosher⁸ and M. A. Gignac⁹, ¹Health Care and Outcomes Research, Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ²Division of Health Care and Outcomes Research,Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ³Research, Mobility Program Clinical Research Unit, Li Ka Shing Knowledge Institute, St. Michaels Hospital, Toronto, ON, Canada, ⁴Medicine, Centre de Recherche du Chu de Québec et Université Laval, Quebec City, QC, Canada, ⁵Pediatric Rheumatology, University of Saskatchewan, Saskatoon, SK, Canada, ⁶Department of Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ⁷Pediatric Rheum/Rm K4-120, BC Childrens Hospital, Vancouver, BC, Canada, ⁸Med, University of Calgary, Calgary, AB, Canada, ⁹Divison of Health Care & Outcomes Research, Health Care and Outcomes Research, Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto; Institute for Work & Health, Toronto, ON, Canada
Background/Purpose: A considerable body of evidence highlights the negative impact of rheumatic disease on employment. However, most research examines middle- and older-aged adults. We lack…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].